TY - JOUR AU - Pasqualucci, L. AU - Dalla-Favera, R. PY - 2018 DA - 2018// TI - Genetics of diffuse large B-cell lymphoma JO - Blood VL - 131 UR - https://doi.org/10.1182/blood-2017-11-764332 DO - 10.1182/blood-2017-11-764332 ID - Pasqualucci2018 ER - TY - JOUR AU - Ma, J. AU - Yan, Z. AU - Zhang, J. PY - 2020 DA - 2020// TI - A genetic predictive model for precision treatment of diffuse large B-cell lymphoma with early progression JO - Biomark Res VL - 8 UR - https://doi.org/10.1186/s40364-020-00214-3 DO - 10.1186/s40364-020-00214-3 ID - Ma2020 ER - TY - JOUR AU - Sehn Laurie, H. AU - Salles, G. PY - 2021 DA - 2021// TI - Diffuse large B-cell lymphoma JO - N Engl J Med. VL - 384 UR - https://doi.org/10.1056/NEJMra2027612 DO - 10.1056/NEJMra2027612 ID - Sehn Laurie2021 ER - TY - JOUR AU - Coiffier, B. AU - Thieblemont, C. AU - Den Neste, E. PY - 2010 DA - 2010// TI - Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte JO - Blood. VL - 116 UR - https://doi.org/10.1182/blood-2010-03-276246 DO - 10.1182/blood-2010-03-276246 ID - Coiffier2010 ER - TY - JOUR AU - Juskevicius, D. AU - Dirnhofer, S. AU - Tzankov, A. PY - 2017 DA - 2017// TI - Genetic background and evolution of relapses in aggressive B-cell lymphomas JO - Haematologica VL - 102 UR - https://doi.org/10.3324/haematol.2016.151647 DO - 10.3324/haematol.2016.151647 ID - Juskevicius2017 ER - TY - JOUR AU - Neste, E. AU - Schmitz, N. AU - Mounier, N. PY - 2016 DA - 2016// TI - Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study JO - Bone Marrow Transplant VL - 51 UR - https://doi.org/10.1038/bmt.2015.213 DO - 10.1038/bmt.2015.213 ID - Neste2016 ER - TY - JOUR AU - Liu, W. AU - Liu, J. AU - Song, Y. PY - 2019 DA - 2019// TI - Mortality of lymphoma and myeloma in China, 2004–2017: an observational study JO - J Hematol Oncol VL - 12 UR - https://doi.org/10.1186/s13045-019-0706-9 DO - 10.1186/s13045-019-0706-9 ID - Liu2019 ER - TY - JOUR AU - Zhou, Z. AU - Sehn, L. H. AU - Rademaker, A. W. PY - 2014 DA - 2014// TI - An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era JO - Blood VL - 123 UR - https://doi.org/10.1182/blood-2013-09-524108 DO - 10.1182/blood-2013-09-524108 ID - Zhou2014 ER - TY - JOUR AU - Ziepert, M. AU - Hasenclever, D. AU - Kuhnt, E. PY - 2010 DA - 2010// TI - Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era JO - J Clin Oncol VL - 28 UR - https://doi.org/10.1200/JCO.2009.26.2493 DO - 10.1200/JCO.2009.26.2493 ID - Ziepert2010 ER - TY - JOUR AU - Rawson, J. L. AU - Fagan, F. M. AU - Burrough, G. C. PY - 2020 DA - 2020// TI - Intensive care unit outcomes in patients with hematological malignancy JO - Blood Sci VL - 2 UR - https://doi.org/10.1097/BS9.0000000000000038 DO - 10.1097/BS9.0000000000000038 ID - Rawson2020 ER - TY - JOUR AU - Chalmers, Z. R. AU - Connelly, C. F. AU - Fabrizio, D. PY - 2017 DA - 2017// TI - Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden JO - Genome Med VL - 9 UR - https://doi.org/10.1186/s13073-017-0424-2 DO - 10.1186/s13073-017-0424-2 ID - Chalmers2017 ER - TY - JOUR AU - Chen, Y. AU - Wang, Y. AU - Luo, H. PY - 2020 DA - 2020// TI - The frequency and inter-relationship of PD-L1 expression and tumour mutational burden across multiple types of advanced solid tumours in China JO - Exp Hematol Oncol VL - 9 UR - https://doi.org/10.1186/s40164-020-00173-3 DO - 10.1186/s40164-020-00173-3 ID - Chen2020 ER - TY - JOUR AU - Wu, Y. AU - Xu, J. AU - Xu, J. PY - 2020 DA - 2020// TI - The predictive value of tumor mutation burden for immune checkpoint inhibitors therapy in non-small cell lung cancer is affected by patients' age JO - Biomark Res VL - 8 UR - https://doi.org/10.1186/s40364-020-00188-2 DO - 10.1186/s40364-020-00188-2 ID - Wu2020 ER - TY - JOUR AU - Tang, B. AU - Yan, X. AU - Sheng, X. PY - 2019 DA - 2019// TI - Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients JO - J Hematol Oncol VL - 12 UR - https://doi.org/10.1186/s13045-018-0693-2 DO - 10.1186/s13045-018-0693-2 ID - Tang2019 ER - TY - JOUR AU - Johnson, D. B. AU - Frampton, G. M. AU - Rioth, M. J. PY - 2016 DA - 2016// TI - Targeted next generation sequencing identifies markers of response to PD-1 blockade JO - Cancer Immunol Res VL - 4 UR - https://doi.org/10.1158/2326-6066.CIR-16-0143 DO - 10.1158/2326-6066.CIR-16-0143 ID - Johnson2016 ER - TY - JOUR AU - Paradiso, V. AU - Garofoli, A. AU - Tosti, N. PY - 2018 DA - 2018// TI - Diagnostic targeted sequencing panel for hepatocellular carcinoma genomic screening JO - J Mol Diagn VL - 20 UR - https://doi.org/10.1016/j.jmoldx.2018.07.003 DO - 10.1016/j.jmoldx.2018.07.003 ID - Paradiso2018 ER - TY - JOUR AU - Li, Y. AU - Jiang, W. AU - Li, T. PY - 2020 DA - 2020// TI - Identification of a small mutation panel of coding sequences to predict the efficacy of immunotherapy for lung adenocarcinoma JO - J Transl Med VL - 18 UR - https://doi.org/10.1186/s12967-019-02199-6 DO - 10.1186/s12967-019-02199-6 ID - Li2020 ER - TY - JOUR AU - Kim, J. AU - Kim, B. AU - Kang, S. Y. PY - 2020 DA - 2020// TI - Tumor mutational burden determined by panel sequencing predicts survival after immunotherapy in patients with advanced gastric cancer JO - Front Oncol VL - 10 UR - https://doi.org/10.3389/fonc.2020.00314 DO - 10.3389/fonc.2020.00314 ID - Kim2020 ER - TY - JOUR AU - Chen, F. AU - Pang, D. AU - Guo, H. PY - 2020 DA - 2020// TI - Clinicopathological characteristics and mutational profiling of adult T-cell lymphoblastic lymphoma in a Chinese population JO - Cancer Manag Res VL - 12 UR - https://doi.org/10.2147/CMAR.S242903 DO - 10.2147/CMAR.S242903 ID - Chen2020 ER - TY - JOUR AU - Sun, P. AU - Chen, C. AU - Xia, Y. PY - 2019 DA - 2019// TI - Mutation profiling of malignant lymphoma by next-generation sequencing of circulating cell-free DNA JO - J Cancer VL - 10 UR - https://doi.org/10.7150/jca.27615 DO - 10.7150/jca.27615 ID - Sun2019 ER - TY - JOUR AU - Chen, C. C. AU - Liang, C. F. AU - Wang, S. Q. PY - 2020 DA - 2020// TI - Expression patterns of immune checkpoints in acute myeloid leukemia JO - J Hematol Oncol VL - 13 UR - https://doi.org/10.1186/s13045-020-00853-x DO - 10.1186/s13045-020-00853-x ID - Chen2020 ER - TY - JOUR AU - Dong, B. AU - Yi, M. AU - Luo, S. PY - 2020 DA - 2020// TI - RDGN-based predictive model for the prognosis of breast cancer JO - Exp Hematol Oncol VL - 9 UR - https://doi.org/10.1186/s40164-020-00169-z DO - 10.1186/s40164-020-00169-z ID - Dong2020 ER - TY - JOUR AU - Yun, D. AU - Jin Fengyan, W. u. AU - Wei, PY - 2019 DA - 2019// TI - Cell cycle regulation and hematologic malignancies JO - Blood Sci VL - 1 UR - https://doi.org/10.1097/BS9.0000000000000009 DO - 10.1097/BS9.0000000000000009 ID - Yun2019 ER - TY - JOUR AU - Seckinger, A. AU - Meissner, T. AU - Moreaux, J. PY - 2012 DA - 2012// TI - Clinical and prognostic role of annexin A2 in multiple myeloma JO - Blood VL - 120 UR - https://doi.org/10.1182/blood-2012-03-415588 DO - 10.1182/blood-2012-03-415588 ID - Seckinger2012 ER - TY - JOUR AU - Delgado, J. AU - Pereira, A. AU - Villamor, N. PY - 2014 DA - 2014// TI - Survival analysis in hematologic malignancies: recommendations for clinicians JO - Haematologica VL - 99 UR - https://doi.org/10.3324/haematol.2013.100784 DO - 10.3324/haematol.2013.100784 ID - Delgado2014 ER - TY - JOUR AU - Wang, P. P. AU - Liu, S. H. AU - Chen, C. T. PY - 2020 DA - 2020// TI - Circulating tumor cells as a new predictive and prognostic factor in patients with small cell lung cancer JO - J Cancer VL - 11 UR - https://doi.org/10.7150/jca.35308 DO - 10.7150/jca.35308 ID - Wang2020 ER - TY - JOUR AU - Wang, Z. AU - Duan, J. AU - Cai, S. PY - 2019 DA - 2019// TI - Assessment of blood tumor mutational burden as a potential biomarker for immunotherapy in patients with non-small cell lung cancer with use of a next-generation sequencing cancer gene panel JO - JAMA Oncol VL - 5 UR - https://doi.org/10.1001/jamaoncol.2018.7098 DO - 10.1001/jamaoncol.2018.7098 ID - Wang2019 ER - TY - JOUR AU - Zhuang, W. AU - Ma, J. AU - Chen, X. PY - 2018 DA - 2018// TI - The tumor mutational burden of chinese advanced cancer patients estimated by a 381-cancer-gene panel JO - J Cancer VL - 9 UR - https://doi.org/10.7150/jca.24932 DO - 10.7150/jca.24932 ID - Zhuang2018 ER - TY - JOUR AU - Talvitie, E. M. AU - Vilhonen, H. AU - Kurki, S. PY - 2020 DA - 2020// TI - High tumor mutation burden predicts favorable outcome among patients with aggressive histological subtypes of lung adenocarcinoma: A population-based single-institution study JO - Neoplasia VL - 22 UR - https://doi.org/10.1016/j.neo.2020.05.004 DO - 10.1016/j.neo.2020.05.004 ID - Talvitie2020 ER - TY - JOUR AU - Bevins, N. AU - Sun, S. AU - Gaieb, Z. PY - 2020 DA - 2020// TI - Comparison of commonly used solid tumor targeted gene sequencing panels for estimating tumor mutation burden shows analytical and prognostic concordance within the cancer genome atlas cohort JO - J Immunother Cancer. VL - 8 UR - https://doi.org/10.1136/jitc-2020-000613 DO - 10.1136/jitc-2020-000613 ID - Bevins2020 ER - TY - JOUR AU - Deng, L. AU - Song, Y. AU - Young, K. H. PY - 2015 DA - 2015// TI - Hepatitis B virus-associated diffuse large B-cell lymphoma: unique clinical features, poor outcome, and hepatitis B surface antigen-driven origin JO - Oncotarget VL - 6 UR - https://doi.org/10.18632/oncotarget.4677 DO - 10.18632/oncotarget.4677 ID - Deng2015 ER - TY - JOUR AU - Ren, W. AU - Ye, X. AU - Su, H. PY - 2018 DA - 2018// TI - Genetic landscape of hepatitis B virus-associated diffuse large B-cell lymphoma JO - Blood VL - 131 UR - https://doi.org/10.1182/blood-2017-11-817601 DO - 10.1182/blood-2017-11-817601 ID - Ren2018 ER - TY - JOUR AU - Yu, Z. AU - Wang, J. AU - Feng, L. X. PY - 2020 DA - 2020// TI - Association of tumor mutational burden with age in solid tumors JO - J Clin Oncol. VL - 38 UR - https://doi.org/10.1200/JCO.2020.38.15_suppl.e13590 DO - 10.1200/JCO.2020.38.15_suppl.e13590 ID - Yu2020 ER - TY - JOUR AU - Savage, K. J. AU - Johnson, N. A. AU - Ben-Neriah, S. PY - 2009 DA - 2009// TI - MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy JO - Blood VL - 114 UR - https://doi.org/10.1182/blood-2009-05-220095 DO - 10.1182/blood-2009-05-220095 ID - Savage2009 ER - TY - JOUR AU - Vermaat, J. S. AU - Somers, S. F. AU - Wreede, L. C. PY - 2020 DA - 2020// TI - MYD88 mutations identify a molecular subgroup of diffuse large B-cell lymphoma with an unfavorable prognosis JO - Haematologica VL - 105 UR - https://doi.org/10.3324/haematol.2018.214122 DO - 10.3324/haematol.2018.214122 ID - Vermaat2020 ER - TY - JOUR AU - Zhao, H. AU - Kan, Y. AU - Wang, X. PY - 2019 DA - 2019// TI - Genetic polymorphism and transcriptional regulation of CREBBP gene in patient with diffuse large B-cell lymphoma JO - Biosci Rep. VL - 39 ID - Zhao2019 ER - TY - JOUR AU - Liu, Y. AU - Gonzalez, Y. AU - Amengual, J. E. PY - 2019 DA - 2019// TI - Chromatin-remodeled state in lymphoma JO - Curr Hematol Malig Rep VL - 14 UR - https://doi.org/10.1007/s11899-019-00541-9 DO - 10.1007/s11899-019-00541-9 ID - Liu2019 ER -